OC-0445: Patterns of care and outcome analysis of SBRT for liver metastases - a DEGRO database initiative

N. Andratschke, H. Alheid, M. Allgäuer, G. Becker, O. Blanck, J. Boda-Hegemann, T. Brunner, S. Combs, M. Duma, S. Gerum, M. Guckenberger, G. Hildebrandt (+8 others)
2016 Radiotherapy and Oncology  
Purpose or Objective: To define maximum tolerated dose (MTD) of stereotactic treatment (SBRT) performed in different clinical settings. Material and Methods: This analysis was based on a doseescalation (Phase I) trial. Patients were enrolled in seven different arms depending on treatment site and previous treatment: 1) intraparenchymal lung tumors; 2) lung tumors near to chest wall or to mediastinum; 3) extra pulmonary tumors; 4) re-irradiation after radiotherapy (< 60 Gy); 5) reirradiation
more » ... ) reirradiation after radiotherapy (> 60 Gy) or re-irradiation of pelvic and pancreatic tumors; 6) boost after a dose < 50Gy; 7) boost after a dose ≥ 50Gy. SBRT was delivered in 5 fractions. The dose was prescribed at isocenter with a 3D static technique using 4-5 non-coplanar beams or with VMAT technique. PTV was defined as the GTV + 5-15 mm. Considering study arms, the first group of patients received 20 Gy, while other cohorts of patients received doses up to 50 Gy. Grade 3 acute and late toxicities were considered as dose limiting toxicity (DLT). If 2/6 or 4/12 DLT were recorded in one cohort, that dose was considered as MTD. Results: 213 patients were enrolled (M/F: 125/88), median age was 69 years (35-90) and 281 lesions were treated (102 primary tumors or local recurrences, 96 nodal and 83 distant metastases); they were mainly lung cancer (31%), gynaecologic cancer (24%), gastrointestinal neoplasms (22%),
doi:10.1016/s0167-8140(16)31694-2 fatcat:jx6luuhvr5hwnn3ojjsfpl3a4m